A new article argues dystrophin immunogenicity is an under-examined issue in the treatment of Duchenne muscular dystrophy.

Today CMS announced that payments to Medicare Advantage and Part D Prescription Plans would increase by 5.06% next year ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Uplizna is the first approved treatment for immunoglobulin G4-related disease (IgG4-RD), a chronic inflammatory condition ...

A new study in England shows a strong link between higher rates of chest x-ray referrals in general practice patients with symptoms, such as persistent cough, and earlier lung cancer diagnoses, along ...

AMCP annual meeting in Houston from March 31 to April 3, John M. O'Brien, Pharm.D., MPH, president and CEO of the National Pharmaceutical Council (NPC), shared concerns and potential reforms in a ...

Panelists discuss how the 18-month retrospective claims analysis of ruxolitinib revealed sustained efficacy in atopic dermatitis management, with significant reductions in disease flares, healthcare ...

The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...

Experts across healthcare debunk 15 common myths about GLP-1 medications—covering everything from access and cost to ...

The study explores whether Prolia/Xgeva (denosumab), a widely used therapy for osteoporosis and bone tumors, can regenerate ...

Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...

Vanrafia reduces proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). It has a wholesale acquisition cost ...